Liquidia Co. (NASDAQ:LQDA) Given Average Recommendation of “Buy” by Brokerages

Liquidia Co. (NASDAQ:LQDA) has received an average recommendation of “Buy” from the nine brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $25.38.

LQDA has been the subject of a number of recent research reports. Scotiabank started coverage on shares of Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of Liquidia in a research report on Thursday, January 9th. Lifesci Capital started coverage on Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price objective on the stock. Wells Fargo & Company began coverage on Liquidia in a report on Friday, December 20th. They issued an “overweight” rating and a $20.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $29.00 price target on shares of Liquidia in a report on Thursday, November 14th.

Insider Transactions at Liquidia

In related news, CEO Roger Jeffs sold 22,343 shares of the business’s stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $263,200.54. Following the transaction, the chief executive officer now directly owns 1,019,177 shares in the company, valued at $12,005,905.06. The trade was a 2.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Rajeev Saggar sold 2,526 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $11.19, for a total value of $28,265.94. Following the completion of the sale, the insider now owns 204,857 shares of the company’s stock, valued at $2,292,349.83. This represents a 1.22 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 73,581 shares of company stock worth $864,565 over the last three months. 30.10% of the stock is currently owned by insiders.

Institutional Trading of Liquidia

A number of institutional investors and hedge funds have recently modified their holdings of LQDA. Whitcomb & Hess Inc. boosted its stake in Liquidia by 10.2% during the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after buying an additional 1,074 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Liquidia by 10.7% in the 2nd quarter. Arizona State Retirement System now owns 13,842 shares of the company’s stock valued at $166,000 after buying an additional 1,341 shares in the last quarter. Quest Partners LLC bought a new position in shares of Liquidia during the 2nd quarter worth about $27,000. Profund Advisors LLC boosted its position in shares of Liquidia by 31.6% during the 2nd quarter. Profund Advisors LLC now owns 14,434 shares of the company’s stock valued at $173,000 after acquiring an additional 3,466 shares in the last quarter. Finally, DMC Group LLC increased its stake in Liquidia by 36.7% in the third quarter. DMC Group LLC now owns 13,883 shares of the company’s stock valued at $139,000 after acquiring an additional 3,725 shares during the period. 64.54% of the stock is currently owned by institutional investors.

Liquidia Stock Up 6.9 %

LQDA stock opened at $12.14 on Friday. The firm has a 50 day moving average of $11.23 and a two-hundred day moving average of $11.02. Liquidia has a 12 month low of $8.26 and a 12 month high of $16.99. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -7.45 and a beta of 0.23.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).